The ADC SGN-35 (Brentuximab vedotin), conjugated with vcMMAE and targeting CD30, induced endoplasmic reticulum stress after releasing MMAE, leading to further ICD-dependent cytotoxicity and ultimately activating anti-tumor immune responses [50]. The gene discussed is TNFRSF8; the disease is neoplasm.